APS Annual Meeting at Experimental Biology



SGLT2 Inhibition and Vascular Regulation: Insights into Cardiorenal Protection (Supported by Janssen Pharmaceuticals, Inc.)

Symposium — Tuesday, April 27, 2021 — 4:00 PM - 5:30 PM — , Room APS-5
Renal Section — Chair: David Cherney — Co-Chair:

Sodium glucose cotransporter-2 (SGLT2) inhibition is associated with a decrease in the risks of cardiovascular and renal disease in patients with type 2 diabetes. These benefits appear to extend across patients with established cardiovascular (CV) disease (EMPA-REG OUTCOME trial), cohorts with a predominance of CV disease (CANVAS Program) and in predominant primary prevention cohorts (DECLARE trial). Remarkably, the mechanisms that are responsible for these protective effects are not yet known, but are the subject of ongoing studies in animals and in humans. The pathways that have been linked with beneficial effects in the heart and kidney include natriuresis and volume-related changes, as well as alternations in energy substrate utilization and in inflammation-related mediators. In this session, participants will review the mechanisms implicated in cardiorenal protection, as well as clinical data supportive of the use these therapies in patients with diabetes and beyond.

Speakers

  • Session Chair
    David Cherney — Physiology, University of Toronto

  • Mechanisms of Renal Protection - Observations in Animals
    Volker Vallon — Nephrology - Hypertension, University of California San Diego School of Medicine

  • Mechanisms of Renal Protection - Observations in Humans
    David Cherney — Physiology, University of Toronto

  • Renal Protection - Observations in Clinical Trials
    Adeera Levin — University of British Columbia

  • SGLT2 Inhibition - Novel Avenues for Future Use
    Petter Bjornstad — School of Medicine, University of Colorado




Host Societies

Copyright © 2021 Experimental Biology (EB) | Experimental Biology® is a federally registered trademark of EB.